{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T12:59:51Z","timestamp":1777640391331,"version":"3.51.4"},"reference-count":33,"publisher":"Elsevier BV","issue":"21","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100003443","name":"Ministry of Education and Science of the Russian Federation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003443","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1016\/j.bmc.2019.115086","type":"journal-article","created":{"date-parts":[[2019,9,4]],"date-time":"2019-09-04T11:58:24Z","timestamp":1567598304000},"page":"115086","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Highly hydrophilic 1,3-oxazol-5-yl benzenesulfonamide inhibitors of carbonic anhydrase II for reduction of glaucoma-related intraocular pressure"],"prefix":"10.1016","volume":"27","author":[{"given":"Stanislav","family":"Kalinin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annika","family":"Valtari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marika","family":"Ruponen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisa","family":"Toropainen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Kovalenko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessio","family":"Nocentini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maxim","family":"Gureev","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dmitry","family":"Dar'in","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arto","family":"Urtti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudiu T.","family":"Supuran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mikhail","family":"Krasavin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmc.2019.115086_b0005","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1016\/S0140-6736(17)31469-1","volume":"390","author":"Jonas","year":"2017","journal-title":"Glaucoma Lancet"},{"key":"10.1016\/j.bmc.2019.115086_b0010","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1089\/jop.2014.0067","article-title":"Pharmacotherapy of glaucoma","volume":"31","author":"Schmidl","year":"2015","journal-title":"J Ocul Pharmacol Therap"},{"key":"10.1016\/j.bmc.2019.115086_b0015","doi-asserted-by":"crossref","first-page":"321","DOI":"10.2165\/00002512-200623040-00005","article-title":"Glaucoma medications","volume":"32","author":"Kanner","year":"2006","journal-title":"Drugs Aging"},{"key":"10.1016\/j.bmc.2019.115086_h0020","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1152\/physrev.1967.47.4.595","article-title":"Carbonic anhydrase: chemistry, physiology, and inhibition","volume":"47","author":"Maren","year":"1967","journal-title":"Physiol Rev"},{"key":"10.1016\/j.bmc.2019.115086_h0025","series-title":"Carbonic anhydrase \u2013 its inhibitors and activators","first-page":"67","article-title":"Development of sulfonamide carbonic anhydrase inhibitors","author":"Supuran","year":"2004"},{"key":"10.1016\/j.bmc.2019.115086_h0030","doi-asserted-by":"crossref","first-page":"4542","DOI":"10.1021\/jm000296j","article-title":"Carbonic anhydrase inhibitors: perfluoroalkyl\/aryl-substituted derivatives of aromatic\/heterocyclic sulfonamides as topical intraocular pressure-lowering agents with prolonged duration of action","volume":"43","author":"Scozzafava","year":"2000","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2019.115086_b0025","series-title":"Handbook of experimental pharmacology","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1007\/978-3-642-69222-2_2","article-title":"Ocular pharmacology","author":"Maurice","year":"1984"},{"key":"10.1016\/j.bmc.2019.115086_b0030","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/0378-5173(85)90005-5","article-title":"Systemic absorption of ocular pilocarpine is modified by polymer matrices","volume":"23","author":"Urtti","year":"1985","journal-title":"Int J Pharm"},{"issue":"6","key":"10.1016\/j.bmc.2019.115086_b0035","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/0039-6257(93)90141-S","article-title":"Minimizing systemic absorption of topically administered ophthalmic drugs","volume":"37","author":"Urtti","year":"1993","journal-title":"Surv Ophthalmol"},{"issue":"6","key":"10.1016\/j.bmc.2019.115086_b0040","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1002\/jps.2600680606","article-title":"Mechanistic and quantitative evaluation of precorneal pilocarpine disposition in albino rabbits","volume":"68","author":"Lee","year":"1979","journal-title":"J Pharm Sci"},{"issue":"2","key":"10.1016\/j.bmc.2019.115086_b0045","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1002\/jps.2600730219","article-title":"Quantitative evaluation of topically applied pilocarpine in the precorneal area","volume":"73","author":"Thombre","year":"1984","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.bmc.2019.115086_b0050","first-page":"584","article-title":"Importance of the noncorneal absorption route in topical ophthalmic drug delivery","volume":"26","author":"Ahmed","year":"1985","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.bmc.2019.115086_b0055","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.jconrel.2010.08.028","article-title":"Barrier analysis of periocular drug delivery to the posterior segment","volume":"148","author":"Ranta","year":"2010","journal-title":"J Control Rel"},{"key":"10.1016\/j.bmc.2019.115086_b0060","first-page":"627","article-title":"Characterization of paracellular and aqueous penetration routes in cornea, conjunctiva, and sclera","volume":"38","author":"H\u00e4m\u00e4l\u00e4inen","year":"1997","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.bmc.2019.115086_b0065","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.ejmech.2015.06.022","article-title":"Probing the 'bipolar' nature of the carbonic anhydrase active site: aromatic sulfonamides containing 1,3-oxazol-5-yl moiety as picomolar inhibitors of cytosolic CA I and CA II isoforms","volume":"101","author":"Krasavin","year":"2015","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2019.115086_b0070","doi-asserted-by":"crossref","first-page":"4560","DOI":"10.1016\/j.bmc.2017.06.054","article-title":"1,3-Oxazole-based selective picomolar inhibitors of cytosolic human carbonic anhydrase II alleviate ocular hypertension in rabbits: potency is supported by X-ray crystallography of two leads","volume":"25","author":"Ferraroni","year":"2017","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.bmc.2019.115086_b0075","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1007\/s40266-015-0282-9","article-title":"Pharmacotherapy and adherence issues in treating elderly patients with glaucoma","volume":"32","author":"Broadway","year":"2015","journal-title":"Drugs Aging"},{"key":"10.1016\/j.bmc.2019.115086_b0080","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.lfs.2019.02.029","article-title":"Glaucoma: current treatment and impact of advanced drug delivery systems","volume":"221","author":"Yadav","year":"2019","journal-title":"Life Sci"},{"key":"10.1016\/j.bmc.2019.115086_b0085","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1016\/j.addr.2006.07.027","article-title":"Challenges and obstacles of ocular pharmacokinetics and drug delivery","volume":"58","author":"Urtti","year":"2006","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.bmc.2019.115086_b0090","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.preteyeres.2016.12.001","article-title":"Pharmacokinetic aspects of retinal drug delivery","volume":"57","author":"Del Amo","year":"2017","journal-title":"Prog Ret Eye Res"},{"key":"10.1016\/j.bmc.2019.115086_b0095","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/newbio235131a0","article-title":"Crystal structure of human carbonic anhydrase C","volume":"235","author":"Liljas","year":"1972","journal-title":"Nat New Biol"},{"key":"10.1016\/j.bmc.2019.115086_b0100","first-page":"9419521","article-title":"Crystallography and its impact on carbonic anhydrase research","author":"Lomelino","year":"2018","journal-title":"Int J Med Chem"},{"key":"10.1016\/j.bmc.2019.115086_b0105","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1007\/s11095-010-0132-8","article-title":"Prediction of the corneal permeability of drug-like compounds","volume":"27","author":"Kidron","year":"2010","journal-title":"Pharm Res"},{"key":"10.1016\/j.bmc.2019.115086_b0110","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1016\/S0021-9258(18)62326-9","article-title":"The carbon dioxide hydration activity of carbonic anhydrase. I. Stop-flow kinetic studies on the native human isoenzymes B and C","volume":"246","author":"Khalifah","year":"1971","journal-title":"Biol Chem"},{"key":"10.1016\/j.bmc.2019.115086_b0115","doi-asserted-by":"crossref","first-page":"407","DOI":"10.3109\/14756366.2011.641015","article-title":"Dithiocarbamates strongly inhibit the \u03b2-class carbonic anhydrases from Mycobacterium tuberculosis","volume":"28","author":"Maresca","year":"2013","journal-title":"J Enzyme Inhib Med Chem"},{"key":"10.1016\/j.bmc.2019.115086_b0120","doi-asserted-by":"crossref","first-page":"845","DOI":"10.3109\/14756366.2011.621122","article-title":"Carbonic anhydrase inhibitors: inhibition of human and bovine isoenzymes by benzenesulphonamides, cyclitols and phenolic compounds","volume":"27","author":"Ekinci","year":"2012","journal-title":"J Enzyme Inhib Med Chem"},{"key":"10.1016\/j.bmc.2019.115086_b0125","doi-asserted-by":"crossref","first-page":"283","DOI":"10.3109\/14756366.2011.643303","article-title":"Carbonic anhydrase inhibitors: in vitro inhibition of \u03b1 isoforms (hCA I, hCA II, bCA III, hCA IV) by flavonoids","volume":"28","author":"Ekinci","year":"2013","journal-title":"J Enzyme Inhib Med Chem"},{"key":"10.1016\/j.bmc.2019.115086_b0130","doi-asserted-by":"crossref","first-page":"294","DOI":"10.3109\/14756366.2012.658788","article-title":"Secondary\/tertiary benzenesulfonamides with inhibitory action against the cytosolic human carbonic anhydrase isoforms I and II","volume":"28","author":"Alp","year":"2013","journal-title":"J Enzyme Inhib Med Chem"},{"key":"10.1016\/j.bmc.2019.115086_b0135","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.bmcl.2005.09.040","article-title":"Carbonic anhydrase inhibitors: valdecoxib binds to a different active site region of the human isoform II as compared to the structurally related cyclooxygenase II \u201cselective\u201d inhibitor celecoxib","volume":"16","author":"Di Fiore","year":"2006","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmc.2019.115086_b0140","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1093\/nar\/28.1.235","article-title":"The protein data bank","volume":"28","author":"Berman","year":"2000","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.bmc.2019.115086_b0145","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s10822-013-9644-8","article-title":"Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichments","volume":"27","author":"Sastry","year":"2013","journal-title":"J Comput Aid Mol Des"},{"key":"10.1016\/j.bmc.2019.115086_b0150","doi-asserted-by":"crossref","unstructured":"Repasky MP, Shelley M, Friesner RA, Flexible ligand docking with Glide, Current protocols in bioinformatics. 2007; Chapter 8: Unit 8,12.","DOI":"10.1002\/0471250953.bi0812s18"},{"key":"10.1016\/j.bmc.2019.115086_b0155","doi-asserted-by":"crossref","first-page":"2463","DOI":"10.1016\/j.xphs.2017.04.061","article-title":"Impact of chemical structure on conjunctival drug permeability: adopting porcine conjunctiva and cassette dosing for construction of in silico model","volume":"106","author":"Ramsay","year":"2017","journal-title":"J Pharm Sci"}],"container-title":["Bioorganic & Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089619312763?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089619312763?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T01:03:34Z","timestamp":1760835814000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0968089619312763"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":33,"journal-issue":{"issue":"21","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["S0968089619312763"],"URL":"https:\/\/doi.org\/10.1016\/j.bmc.2019.115086","relation":{},"ISSN":["0968-0896"],"issn-type":[{"value":"0968-0896","type":"print"}],"subject":[],"published":{"date-parts":[[2019,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Highly hydrophilic 1,3-oxazol-5-yl benzenesulfonamide inhibitors of carbonic anhydrase II for reduction of glaucoma-related intraocular pressure","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmc.2019.115086","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"115086"}}